RT @ericdeinmd: PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE âï¸Meets primary endpt: SRI(4) âï¸Se
Tweet Content
PAISLEY LB004
@EricFMorand on deucravacitinib phase 2 for SLE
⭐️Meets primary endpt: SRI(4)
⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved
⭐️Safety data wo VTE, CVD events
Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE
@RheumNow https://t.co/3YpPSJcenF
Show on Archive Page
On
Display in Search Results
On
PDQ
Off